ArticleAging2021
Identification of colorectal cancer associated biomarkers: an integrated analysis of miRNA expression.
Article in Aging, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Diagnostic Relevance of miR-185, miR-141, and miR-21 in Colon Carcinoma: Insights into Tumor Sidedness and Reference Gene Selection.Biomedicines · 2025Article
- Decision tree-based machine learning methods for identifying colorectal cancer-associated microRNA signatures and their regulatory networks.Scientific reports · 2025Article
- Review
- Colonic Aging and Colorectal Cancer: An Unignorable Interplay and Its Translational Implications.Biology · 2025Review
- LINE-1 methylation status and survival outcomes in colorectal cancer patients: A systematic review and meta-analysis.Heliyon · 2025Article
- Diagnostic and Prognostic Significance of a Four-miRNA Signature in Colorectal Cancer.International journal of molecular sciences · 2025Article
- Evaluating the effect of acute myeloblastic leukemia-derived exosomes on the human bone marrow mesenchymal stromal cell proliferation.Molecular biology reports · 2024Article
- LNA-i-miR-221 activity in colorectal cancer: A reverse translational investigation.Molecular therapy. Nucleic acids · 2024Article
- Molecular detection of exosomal miRNAs of blood serum for prognosis of colorectal cancer.Scientific reports · 2024Article
- Novel insights on perils and promises of miRNA in understanding colon cancer metastasis and progression.Medical oncology (Northwood, London, England) · 2023Review
- Novel biomarkers used for early diagnosis and tyrosine kinase inhibitors as targeted therapies in colorectal cancer.Frontiers in pharmacology · 2023Review
- FOXO1-Induced miR-502-3p Suppresses Colorectal Cancer Cell Growth through Targeting CDK6.Journal of oncology · 2023Article
- Empagliflozin Improves the MicroRNA Signature of Endothelial Dysfunction in Patients with Heart Failure with Preserved Ejection Fraction and Diabetes.The Journal of pharmacology and experimental therapeutics · 2023Article
- Circulating miRNA Expression Profiles and Machine Learning Models in Association with Response to Irinotecan-Based Treatment in Metastatic Colorectal Cancer.International journal of molecular sciences · 2022Article
- MicroRNAs: Novel players in the diagnosis and treatment of cancer cachexia (Review).Experimental and therapeutic medicine · 2022Review
- The Underlying Roles of Exosome-Associated PIGR in Fatty Acid Metabolism and Immune Signaling in Colorectal Cancer.Journal of oncology · 2022Article
- Comprehensive analysis of the potential cuproptosis-related biomarker LIAS that regulates prognosis and immunotherapy of pan-cancers.Frontiers in oncology · 2022Article
- Functional role of miR-34a in diabetes and frailty.Frontiers in aging · 2022Review
- Transcriptome Sequencing Analysis of the Effect ofGenetics research · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer is one of the leading causes of cancer-related deaths worldwide. This complex disease still holds severe problems concerning diagnosis due to the high invasiveness nature of colonoscopy and the low accuracy of the alternative diagnostic methods. Additionally, patient heterogeneity even within the same stage is not properly reflected in the current stratification system. This scenario highlights the need for new biomarkers to improve non-invasive screenings and clinical management of patients. MicroRNAs (miRNAs) have emerged as good candidate biomarkers in cancer as they are stable molecules, easily measurable and detected in body fluids thus allowing for non-invasive diagnosis and/or prognosis. In this study, we performed an integrated analysis first using 4 different datasets (discovery cohorts) to identify miRNAs associated with colorectal cancer development, unveil their role in this disease by identifying putative targets and regulatory networks and investigate their ability to serve as biomarkers. We have identified 26 differentially expressed miRNAs which interact with frequently deregulated genes known to participate in commonly altered pathways in colorectal cancer. Most of these miRNAs have high diagnostic power, and their prognostic potential is evidenced by panels of 5 miRNAs able to predict the outcome of stage II and III colorectal cancer patients. Notably, 8 miRNAs were validated in three additional independent cohorts (validation cohorts) including a plasma cohort thus reinforcing the value of miRNAs as non-invasive biomarkers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.